Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12614000932662
Ethics application status
Approved
Date submitted
26/08/2014
Date registered
1/09/2014
Date last updated
3/05/2017
Type of registration
Prospectively registered

Titles & IDs
Public title
The effect of Mepitel Film on skin reaction severity and moist desquamation rates in patients undergoing radiation therapy for head and neck cancer: a pilot study
Scientific title
The effect of Mepitel Film compared with sorbolene cream on acute radiation-induced skin reaction severity and moist desquamation rates in patients undergoing radiation therapy for head and neck cancer: a randomized intra-patient controlled pilot study
Secondary ID [1] 285232 0
nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute radiation-induced skin reactions 292862 0
Cancer of the Head and Neck region 292897 0
Condition category
Condition code
Cancer 293160 293160 0 0
Head and neck
Skin 293161 293161 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
We changed the intervention from a management. to a prophylactic trial. The film is now applied from day one of radiation therapy until the end of the trial or until moist desquamation occurs. If moist desquamation occurs then these patches will be covered by the standard dressing that is used in each department.
The skin area of interest will be identified from the treatment plans and comprise of a skin area of at least 5 cm2 with a uniform high dose (>40Gy). Thi sarea will be divided into two similar halves, one half will be randomized to film and the other to cream.
Intervention code [1] 290107 0
Treatment: Devices
Intervention code [2] 290135 0
Prevention
Comparator / control treatment
Sorbolene will be applied twice a day from day one of radiation therapyuntil the end of the trial or until moist desquamation occurs. If moist desquamation occurs then these patches will be covered by the standard dressing that is used in each department.
Control group
Active

Outcomes
Primary outcome [1] 293017 0
Skin reaction severity as determined by Radiation Induced Skin Reaction Assessment Scale (RISRAS) or Radiation Therapy Oncology Group (RTOG) score.
Timepoint [1] 293017 0
RISRAS and RTOG scores will be determined 3x a week from the moment of faint erythema till the end of radiation treatment and once a week for 4 weeks after completion of radiation therapy.
Secondary outcome [1] 310158 0
Percentage of patients who develop moist desquamation either in the control area and/or in the treatment area and the time it takes for moist desquamation to develop.
Timepoint [1] 310158 0
Time to development of moist desquamation.
Secondary outcome [2] 310159 0
Effect of psychosocial stress on skin reaction severity as determined by validated Distress Thermometer.
Timepoint [2] 310159 0
This measures will be used at baseline and weekly after that.
Secondary outcome [3] 310253 0
Time to healing of moist desquamation
Timepoint [3] 310253 0
Number of days it takes for the moist desquamation to heal

Eligibility
Key inclusion criteria
patients receiving radiation and chemoradiation
squamous cell carcinoma of the oropharynx, nasopharynx and oral cavity
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Radiation or chemoradiation <30Gy
Distant metastatic disease
Previous radiation to the head and neck area
Skin consitions that may aggrevate radiation-induced skin reactions
Karnofski score<70%
Patients with facial hair on the treatment site

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Protocol has changed from a management to a preventative trial. Based on the RT plan, an area of high dose (>30Gy) of at least 5 by 10 cm will be selected and divided into 2 equal halves. One half will be randomized to Mepitel Film, the other to sorbolene cream.

Randomization of which half will be covered in film and which half in cream is done centrally based on computer-generated random numbers, provided by a biostatistician at the University of Otago, Wellington. The research radiation therapist sends a randomization request to the PI, Dr Herst who will allocate the superior/lateral or the inferior/medial to either film of cream based on the computer-generated numbers.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated random numbers produced by the University's biostatistician, Dr James Stanley
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Participants will act as their own controls. The treatment plan will be used to identify a skin area of >5cm2 that has the highest skin dose. This area will be divided into two equal parts. One part will be randomly assigned to the Mepitel Film arm and the other half will be treated with sorbolene cream. Randomization will be based on computer generated random numbers. The trial cannot be blinded because of the obvious differences between film and cream.
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
This is a pilot study to determine the percentage of moist desquamation in the skin treated with sorbolene cream and that treated with Mepitel Film. Based on the results of this study we will be able to determine the number of participants needed to power a larger international study to 80% with an alpha of 0.05.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/11/2014
Actual
15/05/2015
Date of last participant enrolment
Anticipated
1/12/2016
Actual
13/12/2016
Date of last data collection
Anticipated
Actual
11/03/2017
Sample size
Target
30
Accrual to date
Final
36
Recruitment outside Australia
Country [1] 6310 0
New Zealand
State/province [1] 6310 0
Christchurch
Country [2] 7374 0
China
State/province [2] 7374 0

Funding & Sponsors
Funding source category [1] 289842 0
University
Name [1] 289842 0
University of Otago
Country [1] 289842 0
New Zealand
Funding source category [2] 289843 0
Hospital
Name [2] 289843 0
Christchurch Hospital
Country [2] 289843 0
New Zealand
Funding source category [3] 289845 0
Hospital
Name [3] 289845 0
Dunedin Hospital
Country [3] 289845 0
New Zealand
Funding source category [4] 289847 0
Commercial sector/Industry
Name [4] 289847 0
Molnlycke Healthcare
Country [4] 289847 0
Sweden
Primary sponsor type
University
Name
University of Otago
Address
23A Mein Street
PO BOX 7343
Wellington South
Wellington 6242
Country
New Zealand
Secondary sponsor category [1] 288532 0
None
Name [1] 288532 0
Address [1] 288532 0
Country [1] 288532 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 291574 0
University of Otago Human Ethics Committee
Ethics committee address [1] 291574 0
Ethics committee country [1] 291574 0
New Zealand
Date submitted for ethics approval [1] 291574 0
27/08/2014
Approval date [1] 291574 0
29/09/2014
Ethics approval number [1] 291574 0
H14/111
Ethics committee name [2] 297576 0
Drum Tower Hospital Ethics Committee
Ethics committee address [2] 297576 0
Ethics committee country [2] 297576 0
China
Date submitted for ethics approval [2] 297576 0
Approval date [2] 297576 0
25/03/2016
Ethics approval number [2] 297576 0
protocol number 2016-019-12

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 50966 0
Dr Patries Herst
Address 50966 0
Department of Radiation Therapy University of Otago, Wellington POBox 7343 Wellington South 6242
Country 50966 0
New Zealand
Phone 50966 0
+64-4-3855475
Fax 50966 0
+64-4-3855375
Email 50966 0
[email protected]
Contact person for public queries
Name 50967 0
Patries Herst
Address 50967 0
Department of Radiation Therapy University of Otago, Wellington POBox 7343 Wellington South 6242
Country 50967 0
New Zealand
Phone 50967 0
+64-4-3855475
Fax 50967 0
+64-4-3855375
Email 50967 0
[email protected]
Contact person for scientific queries
Name 50968 0
Patries Herst
Address 50968 0
Department of Radiation Therapy University of Otago, Wellington POBox 7343 Wellington South 6242
Country 50968 0
New Zealand
Phone 50968 0
+64-4-3855475
Fax 50968 0
+64-4-3855375
Email 50968 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseThe effect of mepitel film on acute radiation-induced skin reactions in head and neck cancer patients: A feasibility study.2018https://dx.doi.org/10.1259/bjr.20170298
EmbaseMepitel Film is superior to Biafine cream in managing acute radiation-induced skin reactions in head and neck cancer patients: a randomised intra-patient controlled clinical trial.2020https://dx.doi.org/10.1002/jmrs.397
N.B. These documents automatically identified may not have been verified by the study sponsor.